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The route of transmission of most naturally acquired 
transmissible spongiform encephalopathy (TSE) infections 
remains speculative. To investigate urine as a potential 
source of TSE exposure, we used a sensitive method for 
detection and quantitation of TSE infectivity. Pooled urine 
collected from 22 hamsters showing clinical signs of 263K 
scrapie contained 3.8 ± 0.9 infectious doses/mL of infectivi-
ty. Titration of homogenates of kidneys and urinary bladders 
from the same animals gave concentrations 20,000-fold 
greater. Histologic and immunohistochemical examination 
of these same tissues showed no indications of inﬂ  ammato-
ry or other pathologic changes except for occasional depos-
its of disease-associated prion protein in kidneys. Although 
the source of TSE infectivity in urine remains unresolved, 
these results establish that TSE infectivity is excreted in 
urine and may thereby play a role in the horizontal transmis-
sion of natural TSEs. The results also indicate potential risk 
for TSE transmission from human urine–derived hormones 
and other medicines.
T
ransmissible spongiform encephalopathies (TSEs) are 
fatal neurologic diseases. In humans, a long asymptom-
atic incubation period is followed by a progressive clinical 
course that typically lasts a few months to a year. TSE in-
fectivity and pathologic changes are concentrated in the ner-
vous system; however, much of the transmission risk results 
from parenteral exposure to the much lower concentrations 
of infectivity found in tissues outside the nervous system. 
Thus, despite the very low concentration of TSE infectiv-
ity in blood (1,2), 4 human cases of transmission of variant 
Creutzfeldt-Jakob disease through blood transfusions have 
been documented (3,4). If TSE infectivity were excreted, 
human urine, which is a source of injectible fertility hor-
mones and other drugs (5,6), could also pose a risk for trans-
mission. Infected urine might also account for the horizontal 
transmission of sheep scrapie and might contribute to the 
natural spread of chronic wasting disease in deer and elk.
Early attempts to transmit Creutzfeldt-Jakob disease 
by cross-species inoculation of rodents and primates with 
urine from diseased patients failed (7,8). More recent at-
tempts in which urine from infected hamsters was injected 
back into hamsters have produced variable results (9,10). 
Two other studies have reported infectivity in urine (11) 
and infectivity with disease-speciﬁ  c prion protein (PrPd) in 
kidneys of mice with simultaneous scrapie and nephritis but 
not in those with scrapie alone (12). To resolve these dis-
crepancies, we used a highly sensitive and precise method 
of measuring low concentrations of TSE infectivity, which 
we have successfully used for quantitation of TSE infec-
tivity in blood (1,2), to measure the concentration of TSE 
infectivity in urine of scrapie-infected hamsters.
Materials and Methods
Urine Collection and Processing
Urine was collected from a cohort of 22 Syrian ham-
sters (Harlan Sprague-Dawley, Haslet, MI, USA) that had 
been infected by intracranial injection with 10% (wt/vol) 
scrapie brain homogenate (263K strain) and from a co-
hort of 8 age-matched, noninoculated control animals. At 
the time of urine collection, the scrapie-infected hamsters 
showed clear clinical evidence of disease but were still able 
to drink and eat (67–74 days postinoculation). Hamsters 
were placed 2 at a time for 24 hours in metabolism cages 
in which they had access to water but not food. Food was 
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withheld to prevent contamination of the urine. Urine was 
maintained at 4oC during collection. Separate metabolic 
cages (Rat metabolic cage no. 2100-R; Lab Products, Sea-
ford, DE, USA) were used for each cohort. The urine pro-
duced daily was stored at –80oC. The individual collections 
were then combined into clinical and control pools of ≈60 
mL and ≈125 mL, respectively. 
Limiting Dilution Titration of Urine
We used the limiting dilution method of titration devel-
oped in our laboratory to measure the concentration of TSE 
infectivity in urine (1,2). In this method, a relatively large 
volume of low-titer sample is injected intracerebrally, 50 μL 
at a time, into a large cohort of weanling hamsters. Immedi-
ately before animal inoculation, aliquots of the clinical and 
control urine pools were thawed and sonicated on ice with 
separate sterile ultrasonication probes for each pool. Sonica-
tion was for 4 cycles of 15 s on and 10 s off for 1 min of total 
sonication, using a microtip probe at 40% amplitude (Vi-
bra-Cell 750W; Sonics & Materials, Newtown, CT, USA). 
Two milliliters of control urine was injected undiluted into 
40 hamsters. Clinical urine (urine from hamsters showing 
clinical signs of disease) was diluted 1:3 with inoculation 
buffer (phosphate-buffered saline [PBS] supplemented with 
1% fetal calf serum and 1× penicillin and streptomycin) to 
remove concentration-related toxicity. Five milliliters from 
the clinical urine pool was diluted to 15 mL, and the entire 
volume was injected into 300 hamsters, 50 μL/animal. Soon 
after inoculation, 8 animals inoculated with urine from the 
infected animals died, which left 292 animals in the study. 
All inoculations were conducted under anesthesia with pen-
tobarbital (40–90 mg/kg). At each step the control urine was 
processed before the infected urine.
All animals were assessed weekly for early signs of 
scrapie. At the ﬁ  rst signs of disease, animals were separated 
from their cage mates, observed daily for disease progres-
sion, and euthanized after disease was conﬁ  rmed clinically. 
After 559 days postinoculation all remaining animals were 
euthanized. Brains were collected from all animals in the 
study and assayed for infection-speciﬁ  c, proteinase K–re-
sistant prion protein (PrPres) by Western blot or ELISA, us-
ing a dissociation-enhanced lanthanide ﬂ  uorescent immu-
noassay (DELFIA) developed in our laboratory (described 
below). The infection status of each animal was tabulated, 
and the probabilities of infection and titer were computed 
as described (1,2; Table 1).
Tissue Collection and Processing
Kidneys and urinary bladders were harvested from 
each of 12 infected animals that donated urine either 71 
or 76 days postinoculation. Animals were euthanized by 
asphyxiation with CO2. The bladder was removed ﬁ  rst and 
immediately frozen in liquid nitrogen. The kidneys were 
collected next; the renal capsule was removed before freez-
ing the tissue in liquid nitrogen. Both tissues were dissect-
ed aseptically with a clean, sterile set of instruments for 
each animal and each organ; particular care was taken to 
not touch other organs or tissues. The tissues (12 bladders 
and 19 kidneys) were pulverized with a cryomill by using 
separate cryo-capsules for each tissue (Cryogenic Sample 
Crusher, Model JFC-300; JAI, Tokyo, Japan). The tissue 
powder was stored at –80oC until use.
End-Point Dilution Titration of Tissues
Pooled bladder powder (1.65 g) and pooled kidney 
powder (0.64 g) were separately mixed with homogeni-
zation buffer (PBS, pH 7.2) to make 10% (wt/vol) tissue 
suspensions before sonication at 40% amplitude, using 
separate sterile microtip probes for each homogenate. The 
kidney homogenate was prepared according to the same 
schedule of sonication used for the urine pools. The blad-
der homogenate was sonicated for 10 s, repeated 2 times 
(20 s total sonication time) at room temperature. Longer 
sonication times or delays in the injection of the bladder 
homogenate caused the sample to solidify, which made it 
impossible to dilute and inject. Immediately after sonica-
tion the homogenates were serially diluted 10-fold in inoc-
ulation buffer, and each dilution was injected into hamsters 
in 1 to 5 cages (4 hamsters/cage) for titration by end-point 
dilution (Table 2).
All dilutions were by weight. The study was terminat-
ed at 426 days postinoculation, and the infection status of 
each animal was conﬁ  rmed by Western blot of the brain for 
PrPres. The titers were calculated by the methods of Reed and 
Muench (13), Pizzi (14), and Spearman and Karber (15).
PrPres Detection Procedures
Immunoblotting
Individual brains were homogenized in PBS, pH 7.2, 
to 10% (wt/vol) by using a FASTH homogenizer (Consul 
AR; Villenueve, Switzerland) according to the manufac-
turer’s instructions. To test for PrPres, brain homogenate 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 9, September 2008  1407 
Table 1. Titer of urine from scrapie-infected hamsters 
Hamster
Volume
assayed, mL  Fold dilution 
Volume
inoculated, mL 
Total no. 
hamsters
No. infected 
hamsters
Titer, 
ID/mL* SD†
Infected 4.87 3 14.6 292 18 3.8 0.9
Noninoculated 2 None 2 40 1 – –
*ID, infectious dose. Titer = –ln(P(0)) × (1/v), where P(0) = (noninfected animals)/(total animals inoculated) and v = inoculation volume, 0.05 mL. 
†SD = square root (titer/V), where V = 4.87 mL, the total volume of the undiluted urine inoculated (1).RESEARCH
was digested with proteinase K at 0.1 mg/mL ﬁ  nal con-
centration as described by Gregori et al. (1). Sample buffer 
containing 2% sodium dodecyl sulfate was added, and the 
samples were heated at 100oC for 10 min and subjected to 
sodium dodecyl sulfate–polyacrylamide gel electrophore-
sis. Western blots of the samples were developed by using 
anti-PrP 3F4 monoclonal antibody (Covance, San Diego, 
CA, USA) for PrP detection (1).
ELISA
After proteinase K digestion and heat denaturation as 
described for immunoblotting, the samples were diluted 
100-fold in assay buffer (DELFIA Assay Buffer; Perki-
nElmer, Waltham, MA, USA). They were then assayed for 
PrP concentration by DELFIA by using a Wallac Victor 
V instrument (PelkinElmer) for signal detection, with pu-
riﬁ  ed 3F4 monoclonal antibody (Covance) as the capture 
antibody and puriﬁ  ed 7D9 monoclonal antibody (Covance) 
labeled with Europium according to the manufacturer’s 
instructions (PerkinElmer) as the detection antibody. The 
molar ratio of Europium:7D9 antibody was 7.4:1 (2).
Histologic and Immunologic Tissue Preparation
Formalin-ﬁ   xed brains were cut and divided on the 
midline; 1 hemisphere was cut in the sagittal plane; the 
other was cut coronally at the anterior basal ganglia, the 
middle of the thalamus, and the brainstem with cerebellum. 
Spleens, kidneys, and bladders were divided in the middle. 
All blocks were embedded in parafﬁ  n and processed for 
conventional staining with hematoxylin and eosin and Lux-
ol fast blue/nuclear fast red (for brain) as well as for immu-
nohistochemical detection of PrP with monoclonal anti-PrP 
antibody 3F4 (1:1,000; Covance). For detection of  PrPd, 
sections were pretreated with 30 min of hydrated autoclav-
ing at 121°C followed by 5 min in 96% formic acid. Immu-
nostained sections were counterstained with hematoxylin.
Animal Husbandry and Decontamination Procedures
Animals were maintained in a Biosafety Level 3 (BSL-3) 
animal facility at the Veterans Affairs Medical Center in 
Baltimore, Maryland, USA. Standard operating procedures 
speciﬁ  cally designed for TSEs, including TSE select agents, 
were followed. The operation of this facility has been de-
scribed in detail (16). Animal cages were changed once a 
week, and cages and bedding were decontaminated by au-
toclaving for 1 h at 134oC. The sonicator probes and dissec-
tion instruments were decontaminated by autoclaving for 2 
h at 134oC immersed in 2 N NaOH, followed by cleaning, 
repackaging, and sterilizing. All laboratory surfaces were 
decontaminated before use with either 2 N NaOH or LpH 
(Steris Corporation, Mentor, OH, USA) (16).
Results
Urine Titration
Urine collections from infected and control animals 
were combined into separate pools. Pools minimized the 
possibility of an idiosyncratic measurement from an indi-
vidual and serve as a resource for future experiments once 
the titer has been determined. Clinically affected animals 
consumed lower amounts of water and produced 4–5-fold 
less urine than control animals. This resulted in slightly el-
evated speciﬁ  c gravity, proteins, glucose, and ketones as 
measured with a standard urine dipstick. Elevated urine 
ketones may also have been caused by fasting. The higher 
concentration of the urine pooled from infected animals re-
sulted in a toxicity that required a 3-fold dilution in buffer 
before it could be injected.
TSE developed in 18 of the 292 animals that survived 
the injection of the 3-fold diluted infected pool. Incubation 
times are shown in Figure 1. As observed in other studies 
(1,2), scrapie incubation times for animals infected with 
low-titer samples begin at ≈150 days and rarely extend past 
500 days. None of the animals from either the infected or 
noninfected cohorts that survived to the end of the experi-
ment were positive by DELFIA. None of the 24 animals that 
died during incubation without clinical evidence of scrapie 
were positive for scrapie infection by Western blot. Only 
those animals with clinical scrapie had the typical PrPres sig-
nal in the brain as assessed by Western blot. The infectivity 
titer of the urine as calculated from the Poisson distribution 
was 3.8 ± 0.9 infectious doses (ID)/mL (Table 1).
Scrapie developed (at 425 days postinoculation) in 1 of 
the 40 hamsters inoculated with control urine. Because none 
of the control donor animals contracted scrapie and because 
their brains were negative for PrPres, it is clear that this infec-
tion resulted from contamination. However, the contamina-
tion was unlikely to have been environmental. Our BSL-3 
is managed under a strict regimen of continuous decontami-
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Table 2. End-point dilution titration of urinary bladder and kidney 
from scrapie-infected hamsters 
Total/no. infected 
Dilution Bladder Kidney 
10
–1 19/19 4/4
10
–1.3 8/8 20/20
10
–1.7 8/8 8/8
10
–2 4/4 8/8
10
–3 4/4 4/3
10
–4 4/2 4/1
10
–5 4/1 4/0
10
–6 4/0 4/0
Titer (log10 ID50/g)* 5.5 5.0
Standard error  0.5 0.4
*ID50, 50% infectious dose. Titers calculated by the Reed and Muench 
method (13); standard errors by the Pizzi method (14). TSE Infectivity in Urine
nation and precautionary cleaning (16). As evidence of the 
effectiveness of these measures, we have conducted several 
titrations, involving hundreds of animals each, in which there 
were no infections at all during >540 days of incubation. One 
such study was ongoing during the titration of the urine pools 
reported in this study (2). If there are environmental sources 
of infectivity, the concentration is below the level of detec-
tion by the data accumulated in infection-free titrations to 
date. Instead, after an intensive review of our procedures, we 
concluded that the most likely source of this contamination 
was a technical lapse during collection of the urine pools. 
The level of contamination (1 infection/2 mL of control pool 
injected vs. 18 infections/4.87 mL of clinical pool injected) 
is consistent with a pooling error at the time of collection. 
Nevertheless, had it been an environmental contamination, 
the associated titer (0.51 ID/mL SD = 0.50 ID/mL) would 
have had a negligible effect on the value determined for the 
infected urine.
Tissue Titrations
The concentration of scrapie infectivity in hamster 
urine is similar to that in plasma of scrapie-infected ham-
sters at the same stage of disease, which suggests plasma 
as a possible source of the infectivity. To investigate other 
possible sources, we also measured the concentration of 
TSE infectivity in separate pools of kidneys and bladders 
collected from the same donor animals. The titrations were 
by the end-point dilution method. The titers calculated by 
the methods of Reed and Muench (13) and Pizzi (14) were 
105.5 ± 0.5 50% infectious doses (ID50)/g of bladder and 105.0 ± 
0.4 ID50/g of kidney. The Spearman and Karber method gave 
almost identical values (15).
Histologic and Immunohistochemical 
Examination of Tissues
Others have reported TSE infectivity in the urine of 
scrapie-infected mice with nephritis but not in infected 
mice without nephritis (11,12). In contrast, our hamster 
colony in general, and the animals in this experiment, 
showed no evidence of inﬂ  ammation, as indicated by clini-
cal assessments or urine parameters. Nitrates were within 
normal limits, and no leukocyturia was noted. Proteinuria 
in the clinical hamsters was likely the consequence of low-
volume urine excretion. To further assess whether ham-
sters infected with scrapie were also affected by kidney 
inﬂ  ammation or other abnormalities of the urinary system, 
we examined the kidneys and the urinary bladders of 8 
scrapie-affected hamsters at 84 days postinoculation and 4 
preclinically infected hamsters at 49 days postinoculation 
for PrPd by immunohistochemical and histologic methods 
(Figure 2). We also examined control tissues from 10 age-
matched uninoculated animals as well as brain and spleen 
tissues from infected and control animals.
All tissues were evaluated for signs of inﬂ  ammation 
and for the pattern of PrPd immunoreactivity; brains were 
also examined for spongiform change. No inﬂ  ammatory 
changes were found in any tissue examined. In 9 infected 
animals (clinical and preclinical), we noted nidus forma-
tion in the lumina of the bladder with a few neutrophilic 
granulocytes. However, leukocytes had not invaded the 
wall of the bladder. Nidus formation is often associated 
with dehydration. 
PrP immunoreactivity was not observed in the bladder 
wall of scrapie-infected or control animals (data not shown). 
Spongiform change and deposition of PrPd was lacking in 
control animal brains (Figure 2, panel A) and was noted 
to various extents, according to the stage of the disease, in 
all scrapie-infected animal brains (Figure 2, panel E). We 
observed ﬁ  ne synaptic PrPd immunoreactivity with focal 
patchy or plaque-like appearance in gray matter structures, 
but we also noted ependymal, subependymal, perivascular, 
and white matter PrPd deposits (data not shown). PrPd im-
munoreactivity was observed in the germinal centers of the 
spleen of all scrapie-infected animals (Figure 2, panel F) 
but not in those of controls (Figure 2, panel B). None of 
the control animals exhibited immunoreactivity for PrPd in 
the kidneys (Figure 2, panels C, D). PrPd immunostaining 
showed ﬁ  ne granular deposits in the collecting tubules of 
the medulla (Figure 2, panels G, H) in 4 (50%) of 8 ani-
mals in the clinical stage of scrapie and in 3 (75%) of 4 
animals in the preclinical stage, for a total of 7 (58.3%) of 
12 scrapie-infected animals.
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Figure 1. Distribution of incubation times of hamsters infected by injected urine. Each dot represents 1 animal with clinical scrapie that 
was euthanized at the corresponding day postinoculation. The 22 additional animals that died during the incubation period and the 252 
animals that survived to the end of the experiment (559 days) showed no clinical or immunochemical evidence of scrapie and were scored 
as scrapie negative. RESEARCH
Discussion
Anticipating that the titer of scrapie infectivity in ex-
creted urine would be low, we measured concentration by 
using limiting dilution titration, a method with which we 
have extensive experience quantitating TSE infectivity in 
blood and blood components. In a limiting dilution titra-
tion, all animals in the bioassay are inoculated with the 
highest concentration of inoculum that is tolerated by the 
intracranial (most efﬁ  cient) route. Infectivity assorts ran-
domly into the inoculated animals; provided that at least 
some, but not all, of the animals are infected, the concentra-
tion can be calculated from the Poisson distribution of the 
infections (1). The method is highly sensitive and far more 
precise than other methods of TSE titration. We considered 
concentrating the urine before bioassay, but to circumvent 
uncertainties about the recovery of endogenous infectivity, 
we decided to inject the urine as collected.
We found TSE infectivity in the urine of hamsters that 
had no evidence of kidney or bladder inﬂ  ammation. In con-
trast, Seeger et al. did not detect infectivity in the urine of 
scrapie-infected mice (11) unless the mice were also af-
fected by nephritis, in which case they found low levels 
of infectivity. Whether the bioassay they used was capable 
of detecting infectivity at the concentration we observed 
for hamsters is not clear. If it was not capable, then detec-
tion of infectivity in mice with nephritis implies a higher 
concentration of infectivity in urine excreted by a nephritic 
kidney. In another study, urine and feces from deer with 
chronic wasting disease failed to demonstrate infectivity 
when orally given to the same susceptible species (17). Al-
though usually an inefﬁ  cient route of inoculation, the oral 
route did successfully transmit chronic wasting disease in-
fectivity in saliva. The authors identiﬁ  ed several possible 
reasons for the unsuccessful transmission by excreta, in-
cluding incubation time, genotype, or sample size.
In our experiments, cross-contamination by feces can 
not be excluded as a source of infectivity. Although the me-
tabolism cage effectively separated urine and feces, some 
contact is possible because of the anatomy of the hamster.
Protein misfolding cyclic ampliﬁ  cation uses sonica-
tion to generate PrPres and infectivity in vitro. Although we 
routinely disperse all samples by ultrasonication before in-
jection, our conditions are much harsher than those used 
to generate PrPres de novo (18) and do not support protein 
misfolding cyclic ampliﬁ  cation of PrPres, or presumably in-
fectivity (L. Gregori and R.G. Rohwer, unpub. data).
The kidney and bladder titers were far greater than 
expected compared with ﬁ  ndings of historical studies in 
which, with only rare exceptions (19–21), most attempts 
at transmission have been unsuccessful. These titers cannot 
be explained by the infectivity in residual blood (10 ID/
mL) (1,2). In addition, we observed PrPd in the kidneys of 
scrapie-infected animals that had no indications of tissue in-
ﬂ  ammation. Heikenwalder et al. found PrPd staining within 
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Figure 2. Immunostaining for prion protein (PrP) in control and scrapie-infected hamsters. Deposition of disease-associated PrP is lacking 
in the brain (A), spleen (B), and kidneys (C,D) of control hamsters. Fine synaptic and plaque-like PrP immunoreactivity in the frontal 
cortex (E), granular immunoreactivity in the germinal center of spleen (F) and in the collecting tubules of kidneys (G,H) in a representative 
scrapie-infected animal. Original magniﬁ  cation ×200 for panels A, B, D, E, F, and H and ×40 for panels C and G.TSE Infectivity in Urine
follicular inﬁ  ltrates only in kidneys of mice affected by ne-
phritis and not in control mice with noncomplicated scrapie 
(12). These data together with those by Seeger et al. (11) 
suggested that renal inﬂ  ammation might be a prerequisite 
for TSE infectivity in renal tissue and its excretion in urine. 
In contrast, our results indicate that renal inﬂ  ammation is 
not necessary for the deposition of PrPd in kidneys or for 
excretion of infectivity. One interpretation is that nephritis 
enhances the accumulation of PrPd at sites of inﬂ  ammation, 
consistent with the excretion of higher levels of infectivity 
inferred above for this same condition (11).
Two studies of scrapie in naturally and experimentally 
infected sheep reported PrPd depositions in the renal pa-
pillae (22) and in the intraepithelial cortex, medulla, and 
papillae (23). Similar to our ﬁ  ndings, both studies indicated 
that not all scrapie tissues examined were positive for PrPd. 
In chronic wasting disease, PrPd staining was uniquely lo-
calized in the ectopic lymphoid follicle of the kidney of a 
whitetail deer (24). All studies indicated either no changes 
(22,24) or mild to no inﬂ  ammatory changes of the kidney 
(23). Thus, our histologic and immunohistochemical results 
for scrapie-infected hamsters are consistent with results 
found for sheep and deer and suggest that under normal 
conditions TSE diseases do not have concomitant inﬂ  am-
matory changes in the kidney.
That urine titer is similar to that of plasma suggests that 
urine infectivity may originate from blood (25), but how the 
infectivity would be excreted is not clear. In general, proteins 
>40 kDa are not excreted and smaller proteins crossing the 
glomeruli are reabsorbed in the renal tubule and returned to 
the blood. If TSE infectivity is particulate (>40 kDa), its pres-
ence in urine might indicate abnormalities in renal ﬁ  ltration, 
perhaps related to the accumulation of PrPd in the collecting 
tubules of the medulla. The accumulation of immunoglobu-
lins in the urine of TSE-infected hamsters and humans may 
also indicate malfunction of the urinary system (9,26). Ex-
cretion of a small C-terminal fragment of the normal cellular 
form of the prion protein in urine of infected and noninfected 
animals has been reported (27), but PrPres or PrPd forms can 
only be inferred from the presence of infectivity. Neverthe-
less, excretion of proteins similar to PrPres or PrPd forms has 
been documented. Follicle-stimulating hormone is a glyco-
sylated protein of 203 amino acids organized mostly as a 
β-sheet, which bears some remarkable similarities to β-rich 
forms of the prion protein. Follicle-stimulating and several 
similar hormones are excreted in urine at great enough con-
centration to be extracted commercially. Alternatively, TSE 
infectivity may be excreted by processes analogous to those 
responsible for the low-level virurias that occur during infec-
tions of the nervous system by mumps, measles, and West 
Nile virus (28–30).
To the extent that results from the hamster model can 
be generalized to other TSE infections (and it has so far 
proven highly predictive), then even the very low concen-
trations of infectivity measured here could result in sub-
stantial environmental contamination. Several liters of 
urine and several thousand doses of TSE infectivity may 
be excreted daily over the course of the illness; even higher 
titers might be excreted by an animal with nephritis. The 
high stability of TSE infectivity would account for its per-
sistence in pasture years after infected animals are removed 
(31). Recent studies have shown that infectivity that is ad-
sorbed and immobilized by soil minerals (32) can still in-
fect hamsters by oral exposure 29 months later (33). Our 
study also warns of a possible risk from TSE contamination 
to fertility hormones and other medicinal products extract-
ed from human urine.
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